Online supplement to: Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, In Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase II Study. *The Journal of Rheumatology*. doi:10.3899/jrheum.200893.

**ONLINE SUPPLEMENTARY MATERIAL**

**Supplementary Data 1.** The number of patients enrolled from each country in Part A was: Mexico (n=8), Poland (n=3) and United States (n=25). The number of patients enrolled from each country in Part B was: Argentina (n=57), Australia (n=3), Austria (n=1), Italy (n=10), Japan (n=25), Korea (n=8), Mexico (n=27), Poland (n=29), Slovakia (n=4), South Africa (n=13), Spain (n=13), and the United States including Puerto Rico (n=60).

Online supplement to: Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, In Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase II Study. *The Journal of Rheumatology*. doi:10.3899/jrheum.200893.

**Supplementary Table 1.** Treatment-emergent adverse events in Part A within the blinded treatment dosing period

| | **Placebo** | **Poseltinib** | | |
|---|---|---|---|---|
| | (N=9) | 5-mg (N=9) | 10-mg (N=10) | 30-mg (N=8) |
| Overview of adverse events | | | | |
| Treatment emergent and follow up-emergent adverse events | 6 (66.7) | 3 (33.3) | 6 (60.0) | 2 (25.0) |
| Death | 0 | 0 | 0 | 0 |
| Serious adverse events | 0 | 0 | 0 | 0 |
| Discontinuation from study due to adverse event | 0 | 0 | 0 | 0 |
| Treatment-emergent adverse events by preferred term | | | | |
| Constipation | 0 | 0 | 0 | 1 (12.5) |
| Diarrhea | 1 (11) | 0 | 0 | 0 |
| Dry mouth | 0 | 1 (11) | 0 | 0 |
| Nausea | 0 | 0 | 1 (10) | 0 |
| Non-cardiac chest pain | 0 | 0 | 1 (10) | 0 |
| Bronchitis | 0 | 0 | 0 | 1 (12.5) |
| Laryngitis | 0 | 0 | 1 (10) | 0 |
| Pharyngitis | 1 (11) | 0 | 0 | 0 |
| Sinusitis | 1 (11) | 0 | 0 | 0 |
| Urinary tract infection | 0 | 0 | 1 (10) | 0 |
| Hypertriglyceridemia | 0 | 0 | 1 (10) | 0 |
| Hypokalemia | 1 (11) | 0 | 0 | 0 |
| Osteopenia | 0 | 1 (11) | 0 | 0 |
| Headache | 0 | 0 | 2 (20.0) | 1 (12.5) |
| Carotid artery aneurysm | 1 (11) | 0 | 0 | 0 |
| Dizziness | 1 (11) | 0 | 0 | 0 |
| Cough | 0 | 0 | 1 (10) | 0 |

Data are n (%)

Online supplement to: Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, In Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase II Study. *The Journal of Rheumatology*. doi:10.3899/jrheum.200893.

**Supplementary Table 2.** Treatment-emergent adverse events that occurred in ≥2.0% of patients in any treatment group in Part B within the blinded treatment dosing period.

| | **Placebo** | **Poseltinib** | | |
|---|---|---|---|---|
| | (N=62) | 5-mg (N=63) | 10-mg (N=62) | 30-mg (N=63) |
| Nasopharyngitis | 2 (3.2) | 3 (4.8) | 1 (1.6) | 5 (7.9) |
| Pharyngitis | 2 (3.2) | 0 | 1 (1.6) | 3 (4.8) |
| Influenza | 0 | 1 (1.6) | 2 (3.2) | 2 (3.2) |
| Gastroenteritis | 2 (3.2) | 0 | 1 (1.6) | 1 (1.6) |
| Upper respiratory tract infection | 1 (1.6) | 0 | 2 (3.2) | 1 (1.6) |
| Oral herpes | 0 | 0 | 1 (1.6) | 2 (3.2) |
| Bronchitis | 0 | 0 | 0 | 2 (3.2) |
| Rash | 1 (1.6) | 0 | 3 (4.8) | 3 (4.8) |
| Rash maculo-papular | 1 (1.6) | 0 | 0 | 3 (4.8) |
| Urticaria | 0 | 0 | 1 (1.6) | 2 (3.2) |
| Rheumatoid arthritis | 1 (1.6) | 3 (4.8) | 4 (6.5) | 2 (3.2) |
| Back pain | 1 (1.6) | 2 (3.2) | 0 | 1 (1.6) |
| Diarrhea | 0 | 1 (1.6) | 0 | 2 (3.2) |
| Dyspepsia | 1 (1.6) | 0 | 0 | 2 (3.2) |
| Abdominal distension | 0 | 0 | 0 | 2 (3.2) |
| Fatigue | 0 | 0 | 0 | 4 (6.3) |
| Pyrexia | 0 | 3 (4.8) | 0 | 1 (1.6) |
| Alanine aminotransferase increased | 0 | 0 | 2 (3.2) | 2 (3.2) |
| Anemia | 0 | 0 | 1 (1.6) | 3 (4.8) |
| Hypokalemia | 0 | 0 | 0 | 2 (3.2) |

Data are n (%)